EWA
ABBV icon

Etesian Wealth Advisors’s AbbVie ABBV Stock Holding History

Etesian Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Sell
9,470
-45
-0.5% -$9.68K 0.7% 37
2026
Q1 		$2.07M Sell
9,515
-16
-0.2% -$3.55K 0.66% 41
2025
Q4 		$2.18M Sell
9,531
-210
-2% -$47.8K 0.68% 38
2025
Q3 		$2.26M Sell
9,741
-81
-0.8% -$16.5K 0.74% 34
2025
Q2 		$1.82M Sell
9,822
-237
-2% -$44K 0.68% 41
2025
Q1 		$2.11M Sell
10,059
-25
-0.2% -$4.86K 0.91% 28
2024
Q4 		$1.79M Buy
10,084
+2
+0% +$368 0.79% 31
2024
Q3 		$1.99M Sell
10,082
-45
-0.4% -$8.4K 0.9% 29
2024
Q2 		$1.74M Buy
10,127
+67
+0.7% +$11.1K 0.98% 31
2024
Q1 		$1.83M Sell
10,060
-1,080
-10% -$186K 1.05% 28
2023
Q4 		$1.72M Sell
11,140
-294
-3% -$42.9K 1.04% 29
2023
Q3 		$1.7M Sell
11,434
-48
-0.4% -$7.05K 1.15% 26
2023
Q2 		$1.55M Buy
11,482
+2
+0% +$293 1.01% 33
2023
Q1 		$1.83M Sell
11,480
-169
-1% -$25.8K 1.22% 24
2022
Q4 		$1.88M Buy
+11,649
New +$1.79M 1.37% 22

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Etesian Wealth Advisors's ABBV Position: Q2 2026 in Review

Etesian Wealth Advisors reduced its AbbVie (ABBV) stake by 0.47% in Q2 2026, selling an estimated $9.68K and leaving 9,470 shares worth $2.38M. The position accounts for 0.7% of the portfolio, ranked #37.

Etesian Wealth Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Etesian Wealth Advisors held 9,470 shares of AbbVie worth $2.38M as of Q2 2026.
  • Etesian Wealth Advisors sold 45 AbbVie shares in Q2 2026, an estimated $9.68K.
  • AbbVie made up 0.7% of Etesian Wealth Advisors's portfolio in Q2 2026, its #37 holding.
  • Etesian Wealth Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Etesian Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.